Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00924313 | Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01240629 | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 43 | University of Southern CaliforniaOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT03074032 | Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 17 | Avionco LLCINDUSTRY | 1 | Jul 11, 2017 | clinicaltrials |
| NCT02225093 | A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer | completed | Phase 1 | 12 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01911728 | Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates | completed | Phase 1 | 14 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00536991 | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | terminated | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00225420 | Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer(NRR) | completed | Phase 1 / Phase 2 | 23 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01642732 | Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer | terminated | Phase 1 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT02429804 | NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 4 | Stanford UniversityOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT03164837 | 68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00670553 | A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer | completed | Phase 1 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | May 17, 2017 | clinicaltrials |
| NCT02022371 | Prostate Cancer Genomic Heterogeneity(PROGENY) | completed | Phase 1 / Phase 2 | 50 | University College London HospitalsOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01913015 | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00937417 | S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Apr 24, 2017 | clinicaltrials |
| NCT00574769 | Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | University of Southern CaliforniaOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01317641 | Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 136 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Mar 29, 2017 | clinicaltrials |
| NCT00959335 | Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions | completed | Phase 1 | 36 | SandozINDUSTRY | 0 | Mar 28, 2017 | clinicaltrials |
| NCT00960310 | Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions | completed | Phase 1 | 36 | SandozINDUSTRY | 0 | Mar 28, 2017 | clinicaltrials |
| NCT02483884 | PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer | terminated | Phase 1 / Phase 2 | 30 | Lantheus Biosciences Ltd.INDUSTRY | 2 | Mar 22, 2017 | clinicaltrials |
| NCT03085966 | Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC | unknown | Phase 1 / Phase 2 | 30 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT01155791 | Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer | terminated | Phase 1 | 2 | Sandy SrinivasOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01817738 | Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 197 | CureVacINDUSTRY | 8 | Feb 17, 2017 | clinicaltrials |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | John P. FruehaufOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT03029533 | Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer | unknown | Phase 1 | 44 | Daewoong Pharmaceutical Co. LTD.INDUSTRY | 0 | Jan 24, 2017 | clinicaltrials |
| NCT02198859 | Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer | completed | Phase 1 | 11 | University of Kansas Medical CenterOTHER | 1 | Jan 9, 2017 | clinicaltrials |
| NCT01913197 | Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy | terminated | Phase 1 / Phase 2 | 2 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT03013712 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer(CARTEPC) | unknown | Phase 1 / Phase 2 | 60 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT01106352 | A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 70 | BayerINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. | terminated | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT01347788 | Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Nov 28, 2016 | clinicaltrials |
| NCT00946309 | Effects of Sulforaphane on Normal Prostate Tissue(PHASE) | completed | Phase 1 / Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT00933426 | Lenalidomide and Paclitaxel in Prostate Cancer | terminated | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2016 | clinicaltrials |
| NCT02721784 | Serial mpMRI (Multi Parametric Magnetic Resonance Imaging) Scanning in Prostate Cancer After Androgen Deprivation Therapy and RadioTherapy(SMART) | unknown | Phase 1 / Phase 2 | 10 | University College, LondonOTHER | 1 | Oct 26, 2016 | clinicaltrials |
| NCT01283373 | A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 84 | Genentech, Inc.INDUSTRY | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00852007 | A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1(MUC1) | completed | Phase 1 / Phase 2 | 20 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 15, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT01511536 | Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 38 | SanofiINDUSTRY | 3 | Jul 28, 2016 | clinicaltrials |
| NCT02840617 | ICG-based Fluorescence Imaging in Localization of Prostate Cancer and Metastatic Lymph Nodes | unknown | Phase 1 | 50 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT00374049 | MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer | completed | Phase 1 | 14 | Olivera FinnOTHER | 1 | Jul 12, 2016 | clinicaltrials |
| NCT00126802 | The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer | unknown | Phase 1 / Phase 2 | 60 | AHS Cancer Control AlbertaOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00676286 | Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 in Prostate Cancer Using High Field MRI (3 Tesla), PET, and Biomarkers | completed | Phase 1 | 26 | AHS Cancer Control AlbertaOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00861471 | Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 24 | NYU Langone HealthOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT02816840 | PET-CT/MRI in the Radiotherapy for Prostate Cancer | unknown | Phase 1 / Phase 2 | 90 | Xuzhou Medical UniversityOTHER | 0 | Jun 29, 2016 | clinicaltrials |
| NCT00664196 | Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning | suspended | Phase 1 | 18 | Roger Williams Medical CenterOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00503984 | A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 22 | University of MiamiOTHER | 1 | Jun 9, 2016 | clinicaltrials |
| NCT02093390 | A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects | completed | Phase 1 | 40 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 6, 2016 | clinicaltrials |
| NCT00943956 | Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer | completed | Phase 1 | 30 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | May 25, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jul 11, 2017source: clinicaltrials